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Abstract
Objective We evaluated different dose effects of rIL-25
on acute ulcerative colitis.
Materials and methods Mice were fed 2.5% dextran
sulfate sodium (DSS) for 5 days while infused i.p. with
repeated doses of rIL-25 (0.2, 0.4 and 0.8 lg) in PBS or
PBS only after every 24 h at the same time as the start of
the DSS exposure. Clinical, macroscopical and micro-
scopical assessment of colitis severity with survival study
was performed. Colonic IL-25 expression and production
of IFN-c, IL-10 and IL-4 was also analyzed.
Results At a dose of 0.2 lg, colitis was aggravated with
high mortality, better improvements were observed at a
dose of 0.4 lg, and colitis-induced diarrhea was reversed at
a dose of 0.8 lg. The expression of IL-25 was found to
decrease in severe colitis. Moreover, IL-25 inhibited pro-
duction of mucosal IFN-c, induced increase in IL-10 but
not IL-4.
Conclusion Improvements in DSS-induced colitis in
response to IL-25 suggest IL-25’s protective role by
mechanisms including inhibition of IFN-c with enhance-
ment of anti-inﬂammatory release.
Keywords Acute colitis  IL-25  rIL-25  Dose 
DSS
Abbreviations
rIL-25 Recombinant interleukin-25
DSS Dextran sulfate sodium
IL Interleukin
i.p. Intraperitoneal
DAI Disease activity index
IBD Inﬂammatory bowel disease
Introduction
Contrary to other IL-17 family members (IL-17A, IL-17B,
IL-17C, IL-17D, and IL-17F), IL-25/IL-17E had been
shown to possess unique biological activities that promote
type 2 immune response [1–4]. Currently, evidence has
also been growing on the involvement of IL-25 in allergic
[5, 6], anti-tumor [7] and anti-inﬂammatory activities [8, 9]
in various human and animal models. As extensive studies
on the biological functions of the IL-17 family are still
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matory responses have been suggested for IL-17A, IL-17B,
and IL-17C [10]. Otherwise, a number of cytokines have
been shown to play an important role in the progression of
IBD with a complex and dynamic network that regulates
mucosal immune responses via cytokines, chemokines, and
growth factors [11]. On the basis of their roles, cytokines
have been grouped into pro-inﬂammatory, regulatory,
healing and repair and those which are predominantly
chemokine [12].
The DSS model is a well-characterized model of colitis
which has been shown to be ideal for studying the colitis
immune mechanism, epithelial repairing process and drug
therapy with cytokine proﬁle resembling human IBD [12,
13]. Clinically, mice administered with DSS tend to
develop colon inﬂammation with symptoms such as weight
loss, diarrhea, and rectal bleeding [14, 15]. Microscopically
epithelial erosion, mucosal inﬁltration and ulcers with
subsequent destruction of crypt architecture of the colonic
mucosa can be revealed [12, 14, 15]. In our previous study,
we hinted out inhibitory effects of IL-25 on the develop-
ment and progression of acute DSS-induced colitis in mice
[16]. In the present investigation, we further used different
concentrations of rIL-25 to perform differential dose
studies, expression of IL-25 in colitis was determined and
levels of colonic INF-c, IL-10 and IL-4 production were
measured in order to trace mechanisms by which IL-25
tend to regulate the development and progression of acute
DSS-induced colitis in mice.
Materials and methods
Animals
Female C57BL/6 mice aged 6–8 weeks were purchased
from Shanghai Experimental Center of Chinese Academy
of Science (Shanghai, China). Throughout the experiments
they were maintained at 22C under a 12 h day/night
cycle. The study protocol was approved by the Ethical and
Research Committee of China Medical University and
materials relating to animal experiments conform to the
standards currently applied in China.
Induction of acute colitis and rIL-25 i.p. treatment
Acute colitis was induced by oral administration of 2.5%
(w/v) DSS (molecular weight 36,000–50,000, MP Bio-
medical ICN, France) in drinking water ad libitum for
5 days. Three groups of DSS ? rIL-25 treatment mice
(n = 6 mice/group) were given i.p. different doses of rIL-
25 (R&D System, MN, USA) (0.2, 0.4 and 0.8 lg in 0.1 ml
PBS) at the same time as the start of the DSS exposure. The
administration of the same doses of rIL-25 was repeated
after every 24 h for the duration of 4 days. Mice in
DSS ? PBS group (n = 6) underwent identical procedures
but were only injected i.p. with 0.1 ml PBS. All mice were
sacriﬁced at day 6.
General assessment of colitis
General assessment of the development and progression of
colitis was performed as previously described in our paper
[16]. A modiﬁed scoring system was adopted based on
change in body weight, stool consistency and bloody stool
(Table 1). Disease activity index (DAI) in each group was
determined as the sum total of scores divided by three. At
day 6 mice from all groups were sacriﬁced by cervical
dislocation.
For macroscopic colitis assessment, the colon from each
mouse was dissected, photographed and the length from the
ileocecal junction to the anal verge was measured and
recorded. Colonic tissue samples from each mouse were
ﬁxed in 4% paraformaldehyde, embedded in parafﬁn wax,
sectioned and then were stained with hematoxylin and
eosin. Histological evaluation was performed in a blinded
fashion using a detailed and validating scoring system by
Cooper et al. [15]. Attributed scoring systems were given
as follows; normal colonic mucosa deﬁned as grade 0;
shortening and loss of the basal one-thirds of crypts with
mild inﬂammation and edema in the mucosa deﬁned as
grade 1; loss of the basal two-third of the crypts with
moderate inﬂammation in the mucosa deﬁned as grade 2;
loss of entire crypts with severe inﬂammation in the
mucosa with remaining surface epithelium deﬁned as grade
3; and the loss of entire crypts and surface epithelium with
Table 1 Scoring system for disease activity index
Score Weight loss Stool consistency Blood stool
0 None Normal No blood
11 * 5% Slightly loose Slightly bloody
26 * 10% Loose stools Bloody
31 1 * 20%
4 [20% Diarrhea Gross bleeding
The disease activity index (DAI) is a mean of individual scores of
weight loss, stool consistency, and bleeding
Stool consistency; A normal stool = stool with an appearance of well
formed pellets; a slightly loose stool = a stool with any absence of
well formed pellets; loose stool = stool with pasty, semi formed, soft
material that not adhere to anal fur; diarrhea = liquid stool that
adheres to anal fur
Gross bleeding = an appearance of visible blood that adheres to anal
fur
The mice were blindly scored for the DAI
880 S. S. Salum Mchenga et al.massive inﬂammation in the mucosa, muscularis propria
and sub mucosa deﬁned as grade 4.
Survival study
For survival study, acute colitis was induced by oral
administration of 2.5% (w/v) DSS (molecular weight
36,000–50,000, MP Biomedical ICN, France) in drinking
water ad libitum for the duration of 7 days. At that time, the
mice were returned to normal drinking water while assessed
for their survival. Three groups of DSS ? rIL-25 treatment
mice (n = 10 mice/group) were given i.p. different doses of
rIL-25 (R&D System, MN, USA) (0.2, 0.4 and 0.8 lgi n
0.1 ml PBS) at the same time as the start of the DSS
exposure. The administration of the same doses of rIL-25
was repeated after every 24 h for the duration of 4 days.
Mice in DSS ? PBS group (n = 10) underwent identical
procedures but were only injected i.p. with 0.1 ml PBS.
Western blot analysis
Frozen samples of distal colonic tissues from each mouse
group were homogenized with RIPA Lysis Buffer
(100 mg/ml) (Applygen Technologies Inc. China) supple-
mented with an aprotinin cocktail of inhibitors (Roche,
Mannheim, Germany) and incubated at 4C for 10 min.
The homogenized solutions were centrifuged at 12,000g at
4C for 10 min. Supernatants were separated and protein
concentration in the lysates quantiﬁed with a Bradford
quantitative protein assay kit (Applygen Technologies Inc.,
China). Total protein lysates 20 lg per lane were loaded
and electrophoresed on a 10% SDS-PAGE before being
electro-transferred to Hybond polyvinylidene diﬂuoride
membranes at 60 V for 2 h. The membrane was blocked
with 5% nonfat milk in Tris-buffered saline supplemented
with 0.05% Tween 20 (pH 7.6) at 4C overnight and
incubated with goat anti-mouse IL-25 polyclonal antibody
(1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at room temperature for 2 h. After washing, mem-
brane was incubated with horseradish peroxidase-
conjugated anti-mouse secondary antibody (1:10,000,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room
temperature for 2 h. After extensive washing, the blot was
developed by using the ECL chemiluminescent detection
kit (TransGen Biotech Co. Ltd., China) according to the
manufacturer’s instructions. Images of target protein were
obtained by the use of MF–ChemiBis 3.2 (DNR–Bio-
Imaging System Ltd., Jerusalem, Israel).
Immunohistoﬂuorescent staining
To evaluate expressions of IL-25 protein in the colonic
mucosa, tissue sections (5 lm) from each mouse group
were pretreated by boiling in citrate buffer 10 mM (pH 6.1)
in a microwave oven. After cooling, non-speciﬁc binding
was blocked with 5% BSA blocking reagent followed by
incubation with primary antibody goat polyclonal anti-
mouse IL-25 or isotype-matched IgG control antibodies
(1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4C in a humidiﬁed chamber. After incubation
with the primary antibody, sections were washed with three
changes of PBS and treated with ﬂuorescein isothiocyanate
(FITC) conjugated donkey anti-mouse secondary antibody
(1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 30 min at 37C in a dark chamber. Thereafter, the
sections were extensively washed, mounted with aqueous
UltraCruz Mounting Medium (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and then were examined with a
ﬂuorescence microscope (BX 61; Olympus, Japan) and
images were taken by a digital CCD Image system (DP 71;
Olympus, Japan) attached to the ﬂuorescence microscope.
Cytokines assay
Murine IFN-c, IL-10 and IL-4 cytokines were analyzed by
ELISA kit (eBioscience Inc. San Diego, USA) according to
the manufacturer’s instructions. Colonic tissue samples
from each group were collected and homogenized with
PBS homogenizing buffer (100 mg/ml) containing 1%
Triton X-100 (AMRESCO Inc., USA) supplemented with a
cocktail of protease inhibitors (AMRESCO Inc., USA).
The homogenized solutions were centrifuged at 12,000g
for 10 min, and the supernatants were separated into ali-
quots and stored at -70C.
Statistics
Results are presented as mean ±SD using SAS Software
(version 9.13; SAS Institute Inc., NC, USA). The statistic
difference between means was analyzed using analysis of
variance (ANOVA) for overall comparison and the Stu-
dent–Newman–Keuls (SNK) test as post-test for individual
comparisons. The mortality data were analyzed by Kaplan–
Meier Survival curves. P\0.05 was considered as statis-
tically signiﬁcant.
Results
General observations
In studying the development and progression of DSS-
induced colitis, mice were orally fed 2.5% DSS for ﬁve
consecutive days in order to establish acute colitis while
minimizing mortality. In our study, we realized that
decrease in body weight in mice treated with DSS ? PBS
IL-25 dose effects on colitis 881was not as dramatic as those that received DSS ? 0.2 lg
rIL-25 and DSS ? 0.8 lg rIL-25 (Fig. 1). Mice that
received DSS exhibited marked variations in clinical
symptoms during the development of colitis (Table 2). The
disease index activity (DIA) in mice treated with 0.4 lg
rIL-25 was signiﬁcantly reduced compared to mice treated
with DSS ? PBS and those treated with DSS ? 0.2 lg
rIL-25 (P\0.05). Marked variations in stool consistency
were also observed between all groups. Mice treated with
0.2 lg rIL-25 showed no improvement. However, mice
treated with 0.4 lg rIL-25 and 0.8 lg rIL-25 exhibited
reduced diarrhea and gross bleeding (Table 2). As shown
in Fig. 2, at necropsy, macroscopic inspection of colons
revealed signs of severe colitis in mice treated with
DSS ? PBS compared to mild colitis in all mice treated
with rIL-25. Since shortening of colon length is an indi-
cation of colonic inﬂammation [17], our study revealed
signiﬁcant difference between groups. The shortening of
colons in mice treated with DSS ? PBS was signiﬁcant
compared to the mice treated with 0.2 lg rIL-25, 0.4 lg
rIL-25, and 0.8 lg rIL-25, respectively (P\0.05)
(Table 2). Our ﬁndings reveal that treatment with rIL-25 at
all doses can result in certain forms of reduction of colon
inﬂammation. Histological analysis was blindly carried out
on sections from the distal colon stained by hematoxylin
and eosin (Fig. 3a–e). We revealed variations in colonic
damage between groups. Mice treated with 0.4 lg rIL-25
displayed less severe colonic damage (grade 2) compared
to the mice treated with 0.2 lg rIL-25 and 0.8 lg rIL-25
(grade 3). Histological score was lower in mice treated
with 0.4 lg rIL-25 compared to mice treated with 0.2 lg
rIL-25 and 0.8 lg rIL-25 (Fig. 3f) (P\0.05). Our histo-
logical ﬁndings correlated with clinical and macroscopic
ﬁndings on dose variation effects of rIL-25 in the devel-
opment and progression of acute DSS-induced colitis.
Survival study
Acute colitis was successively induced by administration
of drinking water supplemented with 2.5% DSS for 7 days.
There was marked variations in survival of mice between
all groups (Fig. 4). In comparison to other groups, mice
treated with 0.4 lg rIL-25 showed improvement and pro-
longed survival. The mice treated with 0.2 lg rIL-25 were
fatally affected with severe bleeding and dramatic loss of
body weight, 100% of mice in this group were dead as
early as at day 8. Mice treated with DSS ? PBS and mice
treated with 0.8 lg rIL-25 revealed no difference in sur-
vival rate while mice treated with 0.4 lg rIL-25 had
prolonged survival. Our study demonstrated efﬁciency of
IL-25 at a dose of 0.4 lg.
Expression of IL-25 in colonic tissues
The western blot analysis was applied to assess the
expression of IL-25 in colonic tissues. A band with an
approximate molecular weight of 37 kd protein was
detected, showing a considerable decrease in protein band
intensity with increase in colitis as evident in the DSS ?
PBS treated group, DSS ? 0.2 lg rIL-25 treated group and
Fig. 1 Changes in body weight of mice with DSS-induced colitis.
The mice were fed DSS for 5 days and were repeatedly infused into
the peritoneal cavity with rIL-25 (at indicated doses) or PBS after
every 24 h for the duration of 4 days. The values represent means
±SD (n = 6 mice/group)
Table 2 Clinical variables in different experimental groups at day 6
Group (n = 6) Mean DAI
a Diarrhea
b Gross bleeding
b Mean colon length (cm)
a
DSS ? PBS 2.6 ± 0.25 6/6 4/6 4.3 ± 0.33
#
DSS ? 0.2 lg rIL-25 2.7 ± 0.08 6/6 5/6 5.0 ± 0.21
DSS ? 0.4 lg rIL-25 2.2 ± 0.15* 3/6 2/6 6.0 ± 0.18
DSS ? 0.8 lg rIL-25 2.5 ± 0.22 2/6 3/6 5.4 ± 0.27
a Data are the mean ± SD
b Number of mice with diarrhea or gross bleeding/total number of mice in each group
* P\0.05 versus DSS ? PBS and DSS ? 0.2 lg rIL-25
# P\0.05 versus DSS ? 0.2 lg rIL-25, DSS ? 0.4 lg rIL-25 and DSS ? 0.8 lg rIL-25
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ings reveal decrease in IL-25 expression in mice with
severe colitis.
Cellular source of IL-25 in colonic mucosa
To conﬁrm the expression of IL-25 and to identify its
cellular source, we further performed immunohistoﬂuo-
rescence study. IL-25 was expressed on the epithelium
surface of normal colonic mucosa and colonic mucosa with
mild inﬂammation (mice treated with 0.4 lg rIL-25)
(Fig. 6a, d). However, no IL-25 expression was noted on
entirely damaged mucosa. For this reason, we conﬁrmed
decrease in IL-25 expression in mice with severe colitis
while assuming colonic epithelial cells as IL-25 cellular
sources.
Cytokines assay
Previously, we reported production of IL-17A, IL-23p19/
p40 and TGF-b1 in the development of acute DSS-induced
colitis [16]. Herein, investigations of IFN-c, L-10 and IL-4
secretion in colonic tissue homogenates revealed signiﬁ-
cant decrease in IFN-c levels (P\0.05) in mice treated
with rIL-25 at different doses (Fig. 7a). In comparison with
DSS ? PBS treated mice, the level of IL-10 contents was
signiﬁcantly elevated in mice treated with 0.2 lg rIL-25
(P\0.05). However, elevation of IL-10 levels in mice
treated with 0.4 lg rIL-25 and 0.8 lg rIL-25 was statisti-
cally very close though not at signiﬁcant levels (Fig. 7b).
IL-4 levels were undetectable in all groups. Thus, treatment
with rIL-25 resulted in decrease in IFN-c colonic
production with subsequent increase in IL-10 in this acute
colitis model.
Discussion
On the basis of clinical symptoms and histopathological
changes, development and progression of colitis has been
classiﬁed into acute, chronic and recovery phases [12].
Thus, the present study was only focused on the acute
phase. It has been reported that differences in gender and
genetic background are major determinants for suscepti-
bility and inﬂammatory response in DSS-induced colitis
models, in which case male mice were more severely
affected than females [18]. Nonetheless, C57BL/6 mice
were found to be more susceptible to DSS infections than
BALB/c mice [12]. IL-25 has been implicated in the ini-
tiation of type 2 immunity [1] which involves coordinated
regulation of innate and adaptive immune responses nec-
essary for controlling pathogen invasion at mucosal sites
and resistance to infections. In our recent study [16], we
reported inhibitory effects of IL-25 on the development of
acute DSS-induced colitis, in which clinical symptoms and
histopathological changes were signiﬁcantly reduced. In
the present investigation, treatment of mice with different
doses of rIL-25, resulted distinct dose related variations in
the development of the clinical symptoms, histopatholo-
gical changes and severity of DSS-induced colitis.
Previously, treatment of different strains of mice with
different doses of puriﬁed IL-25 protein at different time
points resulted in Th2-type inﬂammatory responses with
massive pathological changes [1]. Remarkably, our clinical
Fig. 2 Pictures of colons from
normal mice (a), DSS ? PBS
treated mice (b) and
DSS ? rIL-25 treated mice at
the dose of 0.2 lg( c), 0.4 lg
(d) and 0.8 lg( e). Mice were
killed at day 6. Treatments of
rIL-25 were found to improve
DSS-induced colitis
macroscopically
IL-25 dose effects on colitis 883ﬁndings showed signiﬁcant reversal of colitis-induced
diarrhea with resistance to the development of colitis-
induced bleeding. On the contrary, at a small dose rIL-25
aggravated DSS-colitis. In addition, mild macroscopic
morphological changes with less signiﬁcant colonic short-
ening were noted in all mice treated with rIL-25.
Consistent with these ﬁndings, histological observations
revealed improvements of colitis with decline in mice
mortality in a dose dependency manner. Thus, these ﬁnd-
ings reveal distinct IL-25 dose effects in protection of acute
DSS-induced colitis.
Following western blot analysis, we detected expression
of IL-25 in colonic tissues of normal mice. However, the
expression of IL-25 was observed to decrease with increase
in severity of colitis suggesting a protective role for IL-25
as evident in the mice treated with rIL-25 at a dose of
0.4 lg. In identifying colonic IL-25 cellular sources, we
performed immunoﬂuorescence study. We have observed
the presence of IL-25 ﬂuorescence on the colonic
epithelium surface. Despite earlier reports on expression of
IL-25 by Th2 cells [1] and mast cells [19], recently mul-
tiple cellular sources have also been identiﬁed in several
tissues including alveolar macrophage with particle inha-
lation [20], activated eosinophils and basophils [21], brain
microglia [9], some subpopulation of gut-associated T cell
[8] and lung epithelial cells [5]. Thus, with the presence of
IL-25 on mucosal epithelial surfaces of normal mice in our
study, we may have found colonic epithelial mucosal cells
as another IL-25 producer.
In attempting to trace the IL-25 inhibitory mechanism in
this acute model, we choose to determine IFN-c contents in
colonic tissue homogenate as a pro-inﬂammatory (Th1)
cytokine which has been widely reported to play a major
role in the development DSS-induced colitis compared to
TNF-a [22–24]. Studies on DSS-induced colitis revealed a
robust production of IFN-c not only in colonic tissue
homogenate [12, 22] but also at the mRNA level with
signiﬁcant expression in colonic tissues [13]. In the present
Fig. 3 Representative
histological changes in H & E
stained colonic tissues from
normal mice (a), DSS ? PBS
treated mice (b) and
DSS ? rIL-25 treated mice at
the dose of 0.2 lg( c), 0.4 lg
(d) and 0.8 lg/0.1 ml PBS (e)
with their histological scores (f).
Treatments of rIL-25 at a dose
0.4 lg was found to improve
DSS-induced colitis compared
to the DSS ? PBS treated mice
and mice received rIL-25 at a
dose of 0.2 and 0.8 lg. Mice
were killed at day 6. The scores
represent means ±SD (n = 6
mice/group). *P\0.05 when
compared to DSS ? PBS and
mice treated with rIL-25 at a
dose of 0.2 lg and 0.8 lg
884 S. S. Salum Mchenga et al.investigation, colonic IFN-c contents were signiﬁcantly
lowered at all rIL-25 doses. This is in line with a report by
Owyang et al. [9] in which infected IL-25 deﬁcient mice
exhibited severe inﬂammation and exacerbated pathology
associated with increased production of IFN-c. In addition,
Owyang et al. also indicated that IL-25 can either directly
inhibit or limit the expression and production of IFN-c or
IL-17. Our previous study [16] showed no inhibition of IL-
17 by IL-25, however, observations from our present study
showed inhibition of IFN-c suggesting anti-inﬂammatory
activity of IL-25 via inhibition or suppression of IFN-c
rather than IL-17 pathway in acute DSS-induced colitis. On
the other hand, the above reports also seemed to support
the hypothesis that IFN-c is among essential mediators in
the initiation of DSS-induced colitis.
Moreover, in our previous study [16], we revealed sig-
niﬁcant increase of TGF-b1 in mice administered with rIL-
25. Since TGF-b1 was suggested to play an interrelated
role with IL-10 in the prevention of colitis [25], herein we
also wished to determine the impact of IL-10 in the regu-
lation of DSS-induced colitis by IL-25. IL-10 is an anti-
inﬂammatory cytokine shown to attenuate mucosal
inﬂammation by inhibiting both antigen presentation and
subsequent release of pro-inﬂammatory cytokines [26]. It
was also reported that, in down-regulating the level of Th1
cytokine production, IL-10 whenever it remains
unchecked, would otherwise inhibit TGF-b response [27].
As TGF-b production is necessary in the regulation of Th1
T cell-mediated mucosal inﬂammation, IL-10 has been
reported to be a secondary factor required in facilitating
TGF-b production [25]. However, some studies have also
suggested that an increase in IL-10 in acute DSS-colitis
might be likely due to an attempt to counteract and dampen
the increased Th1 response [13]. Consistent with our data,
study of acute DSS-induced colitis was also revealed that
expression of IL-10 is up-regulated with an increase in
severity of colonic mucosal injury [13]. On top of that,
Fig. 4 Kaplan–Meier survival curve. Mice were fed DSS to day 7
then returned to normal drinking water while assessed for their
survival. rIL-25, at indicated doses, or PBS was given i.p. as repeated
injections after every 24 h for the duration of 4 days. DSS ? PBS
(n = 10) and DSS ? rIL-25 at a dose of 0.2 lg( n = 10), 0.4 lg
(n = 10) and 0.8 lg( n = 10). Mice treated with rIL-25 at a dose of
0.4 lg exhibited improved and prolonged survival
Fig. 5 Western blots analysis. IL-25 expression was visually dimin-
ished in mice with severe colitis. rIL-25, at indicated doses, or PBS
were injected i.p. repeatedly after every 24 h for the duration of
4 days. Mice were killed at day 6
Fig. 6 Immunoﬂuorescent stained distal colonic tissues sections in
normal mice (a), DSS ? PBS treated mice (b) and DSS ? rIL-25
treated mice at the dose of 0.2 lg( c), 0.4 lg( d) and 0.8 lg( e),
respectively. IL-25 was expressed on the colonic mucosal epithelium
surface in normal mice (a) and DSS ? 0.4 lg rIL-25 treated mice (d).
rIL-25, at indicated doses, or PBS were injected i.p. repeatedly after
every 24 h for the duration of 4 days. Mice were killed at day 6
IL-25 dose effects on colitis 885despite elevation of IL-10 production in the DSS ? PBS
treated mice, there was much increase of IL-10 production
in DSS ? rIL-25 treated mice. Hence association of IL-25
with IL-10 still remains unknown. Evidently, IL-25 deﬁ-
cient mice have been shown to exhibit severe destructive
inﬂammation with an increased level of IL-10 though in
conclusion it was not found to act in IL-25-dependent
manner [8]. Moreover, studies by Fort et al. [1] also found
no change in the gene expression of IL-10 in the mice
treated with IL-25. Since we could not conﬁrm the asso-
ciation of increased IL-10 with IL-25 we suggested further
studies on the relationship of IL-25 with IL-10 and the
environment which determine the biological consequences
of IL-10 elevation in DSS-induced colitis.
Finally, we analyzed colonic production of IL-4 based
on reported induction of IL-4 by IL-25[1]. Unlike IL-10,
we have been unable to detect the level of IL-4 in this acute
model. Meanwhile, only a very low level of IL-4 was
reported in colonic tissue homogenates from C57BL/6 and
BALB/c with acute DSS-induced colitis [12]. Similarly, at
the mRNA level, no signiﬁcant expression of IL-4 mRNA
transcript was observed on colonic tissues from mice with
either acute DSS-induced colitis [12, 13] or rIL-25 infusion
[1]. IL-4 still remains among the anti-inﬂammatory cyto-
kines whose roles are less well characterized in IBD [26].
IL-4 is believed to be a key cytokine in controlling the
efﬁciency of the type 2 response [28] and to inﬂuence the
balance of Th1 and Th2 cells towards an anti-inﬂammatory
one [13]. Since IL-25 has been reported to induce IL-4 and
Th2 cytokine response [1], it is obvious that there was no
early induction of IL-4 by exogenous IL-25.
In conclusion, our study demonstrated IL-25 dose
dependence improvements in colitis. A possible mecha-
nism is either through direct inhibition or suppression of
the expression and production of IFN-c with subsequent
enhancement of anti-inﬂammatory cytokine release. In
addition to that, we revealed a decrease in mucosa IL-25
expression in acute colitis. These results suggest further
study to explore the possible IL-25 protective role in the
pathophysiology of acute ulcerative colitis.
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